A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension

2006 ◽  
Vol 22 (11) ◽  
pp. 2095-2100 ◽  
Author(s):  
Andrew J. Palmer ◽  
William J. Valentine ◽  
Daniel M. D. Tucker ◽  
Joshua A. Ray ◽  
Stéphane Roze ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Consequence Analysis ◽  
Cost Consequence

scholarly journals Structured self monitoring of blood glucose in Iranian people with type 2 diabetes; A cost consequence analysis

2012 ◽  
Vol 20 (1) ◽  
Author(s):  
Rokhsareh Aghili ◽  
Mohammad E Khamseh ◽  
Mojtaba Malek ◽  
Shahin Yarahmadi ◽  
Amir Farshchi
Keyword(s):  
Type 2 Diabetes ◽  
Blood Glucose ◽  
Self Monitoring ◽  
Consequence Analysis ◽  
Cost Consequence

Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States

2012 ◽  
Vol 15 (4) ◽  
pp. 654-663 ◽  
Author(s):  
Anne-Laure Guillermin ◽  
Adam Lloyd ◽  
Jennie H. Best ◽  
Mary Beth DeYoung ◽  
Yevgeniy Samyshkin ◽  
...  
Keyword(s):  
United States ◽  
Type 2 Diabetes ◽  
The United States ◽  
Consequence Analysis ◽  
Cost Consequence ◽  
Diabetes Patients

scholarly journals PMD48 Structured SMBG in Iranian People With Type 2 Diabetes: A Cost Consequence Analysis

2012 ◽  
Vol 15 (7) ◽  
pp. A353
Author(s):  
R. Aghili ◽  
M.E. Khamseh ◽  
M. Malek ◽  
S. Yarahmadi ◽  
A. Farshchi
Keyword(s):  
Type 2 Diabetes ◽  
Consequence Analysis ◽  
Cost Consequence

scholarly journals Cost Consequence Analysis of Sitagliptin +Metformin Vs Sulfonylureas+Metformin in Type 2 Diabetic Patients in Italy

2016 ◽  
Vol 19 (7) ◽  
pp. A671
Author(s):  
V Lorenzoni ◽  
F Baccetti ◽  
S Genovese ◽  
E Torre ◽  
MA Veneziano ◽  
...  
Keyword(s):  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Consequence Analysis ◽  
Cost Consequence ◽  
Type 2 Diabetic
Sign in / Sign up

Export Citation Format

Share Document